Long Term of Follow-Up of Melanoma-Associated Retinopathy: A Case Report


Por: Albors, MS, Jarroudi, RBE, Sánchez, SG, Blázquez-Albisu, A, Fernandez, SE, Rodríguez, SP, Martín, EC and Monzo, JLM

Publicada: 7 feb 2026 Ahead of Print: 1 dic 2025
Resumen:
PurposeCase report.MethodsMelanoma-associated retinopathy (MAR) is a rareparaneoplastic autoimmune disorder characterized by retinal dysfunction inpatients with cutaneous melanoma. While typically presenting with photopsias, nyctalopia, and peripheral vision loss, diagnosis remains challenging due tooften normal fundoscopic findings and variable autoantibody detection. Thisreport describes a unique case of recurrent MAR managed successfully withintravitreal dexamethasone over a decade-long follow-up.ResultsA 48-year-old man with stage IV cutaneousmelanoma with BRAF V600E mutation achieved complete systemic remission with vemurafenib. During ophthalmological screening, he reported nyctalopia andphotopsias; clinical examination and optical coherence tomography wereunremarkable. Full-field electroretinography (ERG) revealed an electronegativewaveform (reduced b-wave), confirming MAR despite negative antiretinalantibodies. Sub-Tenon's triamcinolone and intravenous immunoglobulin failed toimprove symptoms, but bilateral intravitreal dexamethasone implants (Ozurdex) resolved visual disturbances and normalized ERG. Over ten years, eight MAR recurrences occurred - each treated successfully with Ozurdex - without melanoma relapse.ConclusionMAR can be presented as the first sign of melanoma relapse. This case underscores MAR's potential for recurrence despite durable melanoma remission and highlights intravitreal dexamethasone as an effective long-term therapy. The absence of autoantibodies and late flares challenges current diagnostic paradigms, emphasizing ERG's critical role. Proactive ophthalmologic surveillance and individualized local therapy canpreserve vision in this underrecognized condition.

Filiaciones:
Albors, MS:
 Inst Catala Oncol, Dept Oncol, Badalona, Spain

Jarroudi, RBE:
 Hosp Univ Germans Trias i Pujol, Dept Ophthalmol, Carretera Canyet,S-N, Badalona 08916, Spain

Sánchez, SG:
 Hosp Univ Germans Trias i Pujol, Dept Ophthalmol, Carretera Canyet,S-N, Badalona 08916, Spain

Blázquez-Albisu, A:
 Hosp Univ Germans Trias i Pujol, Dept Ophthalmol, Carretera Canyet,S-N, Badalona 08916, Spain

:
 Inst Catala Oncol, Dept Oncol, Badalona, Spain

:
 Hosp Univ Germans Trias i Pujol, Dept Neurosci, Multiple Sclerosis Neuroimmunol Unit, Badalona, Spain

Martín, EC:
 Hosp Univ Bellvitge, Dept Ophthalmol, Barcelona, Spain

Monzo, JLM:
 Inst Catala Oncol, Dept Oncol, Badalona, Spain
ISSN: 09273948





Ocular Immunology and Inflammation
Editorial
Taylor & Francis, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA, Reino Unido
Tipo de documento: Article
Volumen: 34 Número: 2
Páginas: 260-264
WOS Id: 001644451000001
ID de PubMed: 41413897

MÉTRICAS